; and (ii) the percentage increase in the consumer price index for all urban consumers (United States city average) between December 2016, and the month prior to the quarter described in subparagraph (B). (D) Treatment of subsequently approved drugs In the case of an applicable part B drug first marketed after September 30, 2016, clause (i) of subparagraph (C) shall be applied by substituting the second full calendar quarter after the day on which the drug was first marketed for the calendar quarter beginning January 1, 2017 and clause (ii) of such subparagraph shall be applied by substituting the month prior to the first month of the second full calendar quarter after the day on which the drug was first marketed for December 2016 . (E) Authority to modify methodology (i) Determination of manufacturer-level billing-code level ASP In the case where the Secretary does not have manufacturer level data with respect to a billing code, the Secretary may request such additional data as needed, allocate total volume for all National Drug Codes, regardless of manufacturer, assigned to the billing Code as determined by the Secretary, or use an alternate methodology as necessary in order to determine the manufacturer-level billing-code level ASP under subparagraph (B). (ii) Determination of inflation-adjusted billing-code level ASP In the case where the Secretary does not have sufficient data with respect to the average sales price for applicable part B drugs assigned to a billing code in order to determine the inflation-adjusted billing-code level ASP for the period described in subparagraph (C)(i), including through the application of subparagraph (D) to such subparagraph (C)(i), the Secretary may modify the methodology or period as necessary for purposes of determining an inflation-adjusted billing-code level ASP for such period. (5) Submission of data A rebate agreement under this subsection shall require a manufacturer of an applicable part B drug to submit to the Secretary at such time, and in such manner, as the